Clarus files for $86M IPO as cash run dries
This article was originally published in Scrip
Driving on fumes, Clarus Therapeutics, the US biopharmaceutical company, is turning to the public markets in attempt to bolster its finances. The company has filed plans to raise up to $86.25 million in an IPO after its cash and equivalents fell to just $483,000 at the end of September.
Register for our free email digests: